Friday, August 5, 2022
PAVM gained 95% in one month
| ID | stock | broker | amount | AVG | PRICE TOTAL | date | time | Filled price | amount filled | volume | Total filled | total Stock | Total $ | final price | Remark | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 | PAVM | RH | $4.00 | $24.52 | $98.08 | 4/11/2024 | $1.92 | 2,000.00 | 0 | $3,840.00 | 2004 | $3,938.08 | $1.97 | |||
| -92% DOWN NET LOSS -90.24$(DOWN) |
12/06/2023 1:12 SPLIT PREVIOUS SHARE 51.9 NEW SHARE 3 | $3,840.00 |
MULN short today 8/4/2022
| ID | stock | DATE | BROKER | Avg | SHARE | market | percent | net loss or gain | open | high | Low | Float | avg volume | 52High | 52 Low | Remark | COMPANY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | MULN | 8/10/2022 | RH | $0.84 | 110.00 | $0.82 | -2.88% | ($2.66) | $0.80 | $0.82 | $0.78 | 65.69M | 54.69 | $15.90 | $0.52 | ONE WEEK+7.10 ONE MONTH-16.70 3 MONTH -26.97 ONE YEAR -92.96 | EV AUTOMOTIVE |
| 2 | MULN | 8/5/2022 | RH | $0.84 | 110.00 | $0.83 | -0.92% | ($0.85) | $0.84 | $0.87 | $0.83 | 31.52M | 54.70M | $15.90 | $0.52 | ONE WEEK+7.10 ONE MONTH-16.70 3 MONTH -26.97 ONE YEAR -92.96 |
Mullen Technologies (MULN) - Company CEO, David Michery, will interview on Benzinga's "Stock Market Movers With Money Mitch" YouTube show Thursday afternoon. Tune in to Benzinga's YouTube channel at 1:30 p.m. EDT to see and hear the interview.
ADAP news 8/4/2022
9:41a ET 8/4/2022 - Benzinga
Adaptimmune Therapeutics: Q2 Earnings Insights
| Mentioned: | ADAP |
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.
Revenue was up $2.44 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
QuarterQ1 2022Q4 2021Q3 2021Q2 2021
EPS Estimate-0.220.14-0.26-0.24
EPS Actual-0.05-0.04-0.30-0.24
Revenue Estimate3.29M96.45M1.37M1.36M
Revenue Actual3.58M1.42M1.20M3.10M
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
ADAP news
Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
| Mentioned: | ADAP |
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Subscribe to:
Posts (Atom)